Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alison Gruen

Dermatology New York, NY Medical Doctor

NPI 1518982412 CMS profile 296082

176 East 71St Street, Ground Floor, New York, NY 10021

Open in the dashboard

General payments

$24,301

1,126 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alison Gruen of New York, NY is reported in the CMS Open Payments database as having received $24,301 across 1,126 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,345 156
2024 General $3,911 175
2023 General $4,643 222
2022 General $4,334 209
2021 General $2,582 138
2020 General $2,606 66
2019 General $2,880 160

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alison Gruen
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Alison Gruen were reported at $3,345. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Alison Gruen Dermatology median Middle half National median
2019 $2,880 $454 $129–$1,240 $163
2020 $2,606 $235 $81–$756 $114
2021 $2,582 $377 $108–$1,108 $132
2022 $4,334 $514 $143–$1,391 $149
2023 $4,643 $607 $159–$1,674 $160
2024 $3,911 $751 $204–$1,903 $164
2025 $3,345 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,628 194 payments
  2. Galderma Laboratories, L.P. $2,805 83 payments
  3. Lilly USA, LLC $1,913 93 payments
  4. Pfizer Inc. $1,715 92 payments
  5. Janssen Biotech, Inc. $1,645 70 payments
  6. Incyte Corporation $1,537 65 payments
  7. Novartis Pharmaceuticals Corporation $1,511 77 payments
  8. Ortho Dermatologics, a division of Bausch Health US, LLC $1,280 76 payments
  9. UCB, Inc. $940 45 payments
  10. Amgen Inc. $843 33 payments
  11. Other $6,485 298 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $22,367 1,119 payments
  2. Consulting Fee $1,663 2 payments
  3. Education $271 5 payments
Products named General payments · program years 2019–2025
  1. TALTZ $1,883 92 payments
  2. TREMFYA $1,645 70 payments
  3. ORACEA $1,640 12 payments
  4. SKYRIZI $1,551 82 payments
  5. OPZELURA $1,537 65 payments
  6. RINVOQ $1,389 72 payments
  7. CIBINQO $1,212 66 payments
  8. DUPIXENT $889 29 payments
  9. COSENTYX $871 43 payments
  10. Otezla $843 33 payments
  11. Other $15,132 743 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

550

Median for Dermatology: 534

Drug cost

$161,028

Median for Dermatology: $67,151

Branded share of claims

15.3%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 26 $148,010
Tacrolimus Generic 23 $2,632
Tretinoin Generic 23 $1,271
Metronidazole Generic 20 $1,111
Fluocinonide Generic 28 $1,088
Clobetasol Propionate Generic 34 $1,051
Triamcinolone Acetonide Generic 129 $1,045
Ketoconazole Generic 54 $887
Clindamycin Phosphate Generic 28 $817
Fluorouracil Generic 12 $783

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$197,997

Of which drugs: $63

Medicare patients

869

Average age 75

Services billed

2,695

595 women, 274 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 53%
Arthritis 45%
Osteoporosis 28%
Ischemic heart disease 25%
Diabetes 19%
Cancer 17%
Depression 13%
COPD 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 59 77 $55

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
$496 — —
Bimzelx
$467 — —
TREMFYA
$390 — —
RINVOQ
$350 — —
CIBINQO
$332 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

1,126 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record